Pain for Profit Alleges AMS and Reuters
Mesh Medical Device News Desk, March 20, 2017 ~ Women Undergo Pain for Profit? Those are the allegations of Reuters writer, Alison Frankel who writes a column ‘On the Case’ for Reuters.
Alison Frankel writes On the Case for for Reuters. On March 13 she writes about Rep. Bob Goodlatte, a Virginia Republican who wants to stop the aggressive marketing by personal injury attorneys, the same folks who advertise for injured mesh clients through late night television ads with 800 numbers.
Many women at trial have told juries that was the first indication they had that their numerous complications might be linked to their pelvic mesh implant after doctors routinely denied there could be any link.
Here is her story.
The legislator sent letters to American Bar Association and to each state bar and the District of Columbia. Here is a press release urging common sense reforms be imposed on trial attorneys.
The representative also sent a letter to the Relion Group which places those tv advertisements.
The article cites the 1977 Bates v. State Bar of Arizona that cites the First Amendment which allows lawyers to advertise for personal injury clients.
Frankel and her reporting partner once focused on pelvic mesh and specifically American Medical Systems which launched an aggressive inquiry into mass tort lead generators. Specifically, according to AMS attorneys,
“Law Firm HQ improperly solicited clients to file mesh claims and worked with a medical funding outfit to lure mesh plaintiffs into unnecessary surgery in order to obtain bigger settlements.”
Without citing an example, other than because AMS says so, Frankel lets this column stand.
Here is her previous news on how women were “lured into needless surgeries.”
Here is a MND story on what AMS alleges.
Rep. Goodlatte wants to know how plaintiffs and law firms work with Relion and is asking for copies of the company’s active contracts with plaintiffs’ lawyers.
As a member of the House Judiciary Committee, he’s given the Relion executive to respond by March 21. Stay tuned. ###